Bicycle Therapeutics (STU:50BA) Short Interest


STU:50BA Bicycle Therapeutics PLC STU:50BA
54 GF Score
Price €3.46
GF Value €13.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:50BA vs ABEO, DMAC, FATE: Short Interest Comparison

For the Biotechnology subindustry, Bicycle Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicycle Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Short Interest falls into.


STU:50BA
54GF Score
Bicycle Therapeutics PLC STU:50BA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bicycle Therapeutics (STU:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.46 is trading 73.9% below its estimated GF Value™ of €13.24. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for STU:50BA:

  • Short Interest:
  • GF Value™: €13.24 vs. price of €3.46 (73.9% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the STU:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
54GF Score

Get the complete analysis for STU:50BA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.46
Price
€13.24
GF Value